Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma

Phase 2 Unknown 30 enrolled University of Virginia Bristol-Myers Squibb · collab Eli Lilly and Company · collab Washington University School of Medicine · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The anti-tumor activity of cetuximab prior to chemoradiotherapy and the safety and tolerability of cetuximab with concurrent chemoradiation will be determined in women with locally advanced or metastatic cervical carcinoma.

Timeline

Start: 2006-02
Primary completion: 2012-02
Completion: —

Publications

Fracasso PM, Duska LR, Thaker PH, Gao F, Zoberi I, Dehdashti F, Siegel BA, Uliel L, Menias CO, Rehm PK, Goodner SA, Creekmore AN, Lothamer HL, Rader JS. An Exploratory Study of Neoadjuvant Cetuximab Followed by Cetuximab and Chemoradiotherapy in Women With Newly Diagnosed Locally Advanced Cervical Cancer. Am J Clin Oncol. 2022 Jul 1;45(7):286-293. doi: 10.1097/COC.0000000000000926. Epub 2022 Jun 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cetuximab	Monoclonal antibody	200 mg/m2	—
Subject	Cetuximab	Monoclonal antibody	250 mg/m2	—

Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma

Summary

Timeline

Publications

Drugs

Indications